WO2000015218A1 - A new composition - Google Patents

A new composition Download PDF

Info

Publication number
WO2000015218A1
WO2000015218A1 PCT/SE1999/001597 SE9901597W WO0015218A1 WO 2000015218 A1 WO2000015218 A1 WO 2000015218A1 SE 9901597 W SE9901597 W SE 9901597W WO 0015218 A1 WO0015218 A1 WO 0015218A1
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
component
pharmaceutical formulation
disorders
composition
Prior art date
Application number
PCT/SE1999/001597
Other languages
French (fr)
Inventor
John Evenden
Seth-Olov Thorberg
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EEP200100157A priority Critical patent/EE200100157A/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to BR9913748-8A priority patent/BR9913748A/en
Priority to JP2000569802A priority patent/JP2002524508A/en
Priority to EP99951319A priority patent/EP1128825A1/en
Priority to SK326-2001A priority patent/SK3262001A3/en
Priority to PL99346763A priority patent/PL346763A1/en
Priority to KR1020017003337A priority patent/KR20010099647A/en
Priority to AU63780/99A priority patent/AU6378099A/en
Priority to CA002342341A priority patent/CA2342341A1/en
Priority to IL14151999A priority patent/IL141519A0/en
Publication of WO2000015218A1 publication Critical patent/WO2000015218A1/en
Priority to IS5879A priority patent/IS5879A/en
Priority to NO20011312A priority patent/NO20011312L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a composition which comprises a first component (a) which is ( ⁇ )-3-NN-dicyclobutylamino-8-fluoro-3,4-dihydro-2H- l-benzopyran-5- carboxamide hydrogen (2_?,3i.)-tartrate monohydrate and a second component (b) which is paroxetine, or a pharmaceutically acceptable salt and/or solvate thereof.
  • the present invention also relates to a process for the preparation of the inventive composition, pharmaceutical formulations containing said composition and to the use of said composition either by concomitant administration or by separate administration as an improvement of the treatment of affective disorders such as depression, anxiety, obsessive compulsive disorder (OCD), etc.
  • antidepressants take 2-4 weeks to reach full clinical effect. In contrast, the side effects occur immediately. Thus, slow onset of action of antidepressants leads to a vulnerable period for patients in which they experience the side effects, but rfot the therapeutic effects of drugs. There is often a heavy burden on the treating physician to persuade the patient to continue with the treatment during this period. Furthermore, in suicidal patients, as the onset of action is gradual, initiative may be regained without the experiencing of full reversal of symptoms, leaving a window of risk for suicide and a frequent requirement for hospitalization.
  • the present invention is directed to a new composition
  • a new composition comprising of a first component (a) which is the specific 5-HT ⁇ antagonist ( ⁇ -3-NN-d_cyclobutylamino-8-fluoro-3,4- dihydro-2H-l-benzopyran-5-carboxamide hydrogen (2_?,3i?)-tartrate monohydrate and a second component (b) which is paroxetine, in the form of the free base, or a pharmaceutically acceptable salt and/or solvate thereof.
  • Said composition attains a faster onset of action and consequently, provides a more efficacious treatment of the patients . suffering form affective disorders, particularly depression.
  • Paroxetine is a 5-HT reuptake inhibitor (SSRI) which is commercially available.
  • Pharmaceutically acceptable salts of paroxetine such as the hydrochloride, hydrobromide, maleate, tartrate, acetate etc. are also included in the inventive composition. Also solvate forms such as the hydrate and hemihydrate of the salts are included.
  • composition according to the present invention may exist in one pharmaceutical formulation comprising the component (a) and component (b), or in two different pharmaceutical formulations, one for component (a) and one for component (b).
  • the pharmaceutical formulation may be in the form of tablets or capsules, powders, mixtures, solutions or other suitable pharmaceutical formulation forms such as patches and nasal formulations.
  • composition of the present invention can be prepared such that component (a) is incorporated into the same pharmaceutical formulation as component (b) by e.g. mixing in a conventional way.
  • the present invention also includes a method of improving the onset of therapeutic action by concomitant administration of a composition comprising of (R)-3-N,N- dicyclobutylamino-8-fluoro-3,4-dihydro-2H- 1 -benzopyran-5-carboxamide hydrogen (2 ⁇ ,3_?)-tartrate monohydrate and paroxetine.
  • a further embodiment of the present invention is a kit containing a dosage unit of (R)-3- NN-dicyclobutylamino-8-fluoro-3,4-dihydro-2H- 1 -benzopyran-5-carboxamide hydrogen (2_?,3i?)-tartrate monohydrate and a dosage unit of a paroxetine, optionally with instructions for use.
  • the compounds in the composition will normally be administered orally, rectally, transdermally, nasally or by injection, in the form of pharmaceutical formulations comprising the active ingredients in a pharmaceutically acceptable dosage form .
  • the dosage form may be a solid, semisolid or liquid formulation.
  • the active substances will constitute between 0.1 and 99% by weight of the formulation, more specifically between 0.5 and 20% by weight for formulations intended for injection and between 0.2 and 50% by weight for formulations suitable for oral administration.
  • the pharmaceutical formulation comprises the active ingredients, optionally in association with adjuvants, excipients e.g. diluents, and/or inert carriers.
  • the selected compounds may be mixed with a solid excipient, e.g. lactose, saccharose, sorbitol, mannitol, starches such as potato starch, corn starch or amylopectin, cellulose derivatives, a binder such as gelatin or poly- vinylpyrrolidone, disintegrants e.g. sodium starch glycolate, cross-linked PVP and cross- caramellose sodium and a lubricant such as magnesium stearate, calcium stearate, polyethylene glycol, waxes, paraffin, and the like, and an antisticking agent such as talc or colloidal silicon dioxide, and then compressed into tablets.
  • a solid excipient e.g. lactose, saccharose, sorbitol, mannitol, starches such as potato starch, corn starch or amylopectin, cellulose derivatives, a binder such as gelatin or poly- vinylpyrrolidone, disintegrants e.g. sodium starch
  • the cores may be coated with a polymer known to the man skilled in the art e.g. HPMC, HC or other cellulose derivatives or PNP, wherein the polymer is dissolved in water or a readily volatile organic solvent or mixture of organic solvents.
  • a polymer known to the man skilled in the art e.g. HPMC, HC or other cellulose derivatives or PNP, wherein the polymer is dissolved in water or a readily volatile organic solvent or mixture of organic solvents.
  • the tablets can be coated with a concentrated sugar solution which may contain e.g. gum arabic, gelatin, talcum, titanium dioxide, and the like.
  • Dyestuffs may be added to these coatings for instance in order to readily distinguish between tablets containing different active substances or different amounts of the active compounds.
  • the active substances may be admixed with e.g. a vegetable oil or polyethylene glycol.
  • Hard gelatin capsules may contain granules of the active substances using any of the above mentioned excipients for tablets e.g. lactose, saccharose, sorbitol, mannitol, starches (e.g. potato starch, corn starch or amylopectin), cellulose derivatives, plasticizers, polyetheneglycol, waxes, lipids or gelatin. Also liquids or semisolids of the drug can be filled into hard gelatin capsules.
  • Dosage units for rectal application can be solutions or suspensions or can be prepared in the form of suppositories comprising the active substances in a mixture with a neutral fatty base, or gelatine rectal capsules comprising the active substances in admixture with vegetable oil or paraffin oil.
  • Liquid formulations for oral application may be in the form of solutions, syrups or suspensions, for example " solutions containing from about 0.2% to about 20% by weight of the active substances herein described, the balance being sugar and mixture of ethanol, water, glycerol and propylene glycol.
  • such liquid formulations may contain colouring agents, flavouring agents, saccharin and carboxymethyl-cellulose as a thickening agent or other excipients known to a person skilled in the art.
  • Solutions for parenteral applications by injection can be prepared in an aqueous solution of a water-soluble pharmaceutically acceptable salt of the active substances, preferably in a concentration of from about 0.5% to about 10% by weight. These solutions may also contain stabilizing agents and/or buffering agents and may conveniently be provided in various dosage unit ampoules. Suitable daily doses of the active compounds in the composition of the invention in therapeutic treatment of humans are about 0.01-100 mg/kg bodyweight for peroral administration and 0.001-100 mg kg bodyweight for parenteral administration.
  • the daily doses of the active ingredient C_ ⁇ -3-NN-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-l- benzopyran-5-carboxamide hydrogen (2i?,3i?)-tartrate monohydrate may very well differ from the daily doses of the active ingredient paroxetine but the doses can also be the same for both of the active ingredients.
  • the present invention provides the use of the composition comprising a first component (a) which is ' ⁇ -3-NN-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-l- benzopyran-5-carboxamide hydrogen (2 ⁇ ,3i?)-tartrate monohydrate and a second component (b) which is paroxetine, in the treatment of 5-hydroxytryptamine mediated disorders, such as affective disorders.
  • a which is ' ⁇ -3-NN-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-l- benzopyran-5-carboxamide hydrogen (2 ⁇ ,3i?)-tartrate monohydrate
  • a second component (b) which is paroxetine in the treatment of 5-hydroxytryptamine mediated disorders, such as affective disorders.
  • affective disorders are disorders in the C ⁇ S such as mood disorders (depression, major depressive episodes, dysthymia, seasonal affective disorder, depressive phases of bipolar disorder), anxiety disorders (obsessive compulsive disorder, panic disorder with/without agoraphobia, social phobia, specific phobia, generalized anxiety disorder, posttraumatic stress disorder), personality disorders (disorders of impulse control, trichotellomania) and sleep disorders.
  • disorders in the C ⁇ S such as eating disorders (obesity, anorexia, bulimia), premenstrual syndrome, sexual disturbances, alcoholism, tobacco abuse, autism, attention deficit, hyperactivity disorder, migraine, memory disorders (age associated memory impairment, presenile and senile dementia such as Alzheimer's disease), pathological aggression, schizophrenia, endocrine disorders (e g hyperprolactinaemia), stroke, dyskinesia, Parkinson's disease, thermoregulatory disorders, pain and hypertension may also be treated with the combination described herein.
  • hydroxytryptamine mediated disorders are urinary incontinence, vasospasm and growth control of tumors (e g lung carcinoma) and it may be possible to treat those with the combination described herein as well.
  • NAD 299 could antagonize the suppression of firing in serotoninerglc dorsal raphe neurones in rats induced by paroxetine (Figure).
  • Figure shows medians +semi-interquartile range based on recordings from 5 animals per group.
  • the paroxetine- induced suppression was statistically significantly antagonised by NAD 299 treatment (p ⁇ 0.05).
  • SSRIs selective serotonin reuptake inhibitors
  • paroxetine selective serotonin reuptake inhibitors
  • SSRIs selective serotonin reuptake inhibitors
  • the 5-hydroxytryptamine (5-HT) transporter protein affected is present both in somatodendritic and terminal regions, and initially the enhanced availability of serotonin in the former areas will inhibit neuronal activity as well as forebrain synthesis and release of 5-HT through activation of inhibitory 5-HTJA autoreceptors.
  • these receptors desensitize with time there is a gradual increase in forebrain serotonin release, as has been shown in animals studies, and the time-course for this phenomenon probably explains the delayed onset of antidepressant actions clinically.
  • a suitable pharmaceutical composition comprising a first component (a) and a second component (b) in a single dosage form include the following:

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

The invention relates to a composition comprising a first component (a) which is (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide hydrogen (2R,3R)-tartrate monohydrate and a second component (b) which is paroxetine in the form of its free base, or a pharmaceutically acceptable salt and/or solvate thereof, the preparation thereof, pharmaceutical formulations containing said composition, use of and a method of treatment of affective disorders such as mood disorders and anxiety disorders with said composition as well as a kit containing said composition.

Description

A NEW COMPOSITION
Field of the Invention
The present invention relates to a composition which comprises a first component (a) which is (^)-3-NN-dicyclobutylamino-8-fluoro-3,4-dihydro-2H- l-benzopyran-5- carboxamide hydrogen (2_?,3i.)-tartrate monohydrate and a second component (b) which is paroxetine, or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also relates to a process for the preparation of the inventive composition, pharmaceutical formulations containing said composition and to the use of said composition either by concomitant administration or by separate administration as an improvement of the treatment of affective disorders such as depression, anxiety, obsessive compulsive disorder (OCD), etc.
Background of the Invention
Today, it is generally considered that antidepressants take 2-4 weeks to reach full clinical effect. In contrast, the side effects occur immediately. Thus, slow onset of action of antidepressants leads to a vulnerable period for patients in which they experience the side effects, but rfot the therapeutic effects of drugs. There is often a heavy burden on the treating physician to persuade the patient to continue with the treatment during this period. Furthermore, in suicidal patients, as the onset of action is gradual, initiative may be regained without the experiencing of full reversal of symptoms, leaving a window of risk for suicide and a frequent requirement for hospitalization. An antidepressant with fast onset of action would not only be beneficial due to the faster symptom reduction, but would also be more acceptable to patients and physicians and reduce the need for and duration of hospitalization. The same long period to reach full clinical effect has been shown in the treatment of other affective disorders such as anxiety and OCD. Prior art
In WO 96/33710 is disclosed that the compound t7? -5-carbamoyl-8-fluoro-3-NN- dicyclobutylamino-3,4-dihydro-2H-l-benzopyran which has high affinity to 5-HT receptors and antagonizes 5-HT|A mediated responses induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors.
Summary of the Invention
The present invention is directed to a new composition comprising of a first component (a) which is the specific 5-HT ^antagonist (^-3-NN-d_cyclobutylamino-8-fluoro-3,4- dihydro-2H-l-benzopyran-5-carboxamide hydrogen (2_?,3i?)-tartrate monohydrate and a second component (b) which is paroxetine, in the form of the free base, or a pharmaceutically acceptable salt and/or solvate thereof. Said composition attains a faster onset of action and consequently, provides a more efficacious treatment of the patients . suffering form affective disorders, particularly depression.
It has been shown in animal studies that acute administration of selective 5-ΗT reuptake inhibitors (SSRIs) decreases the electrical impulse propagation in 5-HT neurones via a negative feedback reaction probably mediated by collateral 5-HT axons releasing 5-HT in raphe nuclei. By inhibiting the somatodendritic 5-HTιA autoreceptors in the raphe nuclei the selective antagonists counteract the decrease in propagetion caused by 5-HT reuptake inhibitors. This indicates that a selective blockade of somatodendritic autoreceptor i.e. 5- HTIA antagonist may have a clinical potential to improve the efficacy of 5-HT reuptake inhibitors (SSRIs) and offer a new rationale for rapid onset of effect in the treatment of affective disorders, for instance the antidepressant actions.
The compound (R)-3-N, N-dicyclobutylamino-8-f_uoro-3 ,4-dihydro-2H- 1 -benzopyran-5- carboxamide hydrogen (2Λ,3_?)-tartrate monohydrate (NAD 299) disclosed herein is described in J. Pharmacol. Exp. Ther., 283, 216-225, (1997) as a selective 5-HTt A receptor antagonist.
(^-3-N,N-dicyclobutylaπιino-8-fluoro-3,4-dihydro-2H-l-benzopyran-5-carboxamide hydrogen (2_?,3_?)-tartrate monohydrate possesses a high affinity to the specific subgroup of 5-HTIA receptor in the CΝS and acts as an antagonist on that 5-HT|A receptor, and also shows favourable bioavailability after oral administration.
Paroxetine is a 5-HT reuptake inhibitor (SSRI) which is commercially available. Pharmaceutically acceptable salts of paroxetine such as the hydrochloride, hydrobromide, maleate, tartrate, acetate etc. are also included in the inventive composition. Also solvate forms such as the hydrate and hemihydrate of the salts are included.
The composition according to the present invention may exist in one pharmaceutical formulation comprising the component (a) and component (b), or in two different pharmaceutical formulations, one for component (a) and one for component (b). The pharmaceutical formulation may be in the form of tablets or capsules, powders, mixtures, solutions or other suitable pharmaceutical formulation forms such as patches and nasal formulations.
The composition of the present invention can be prepared such that component (a) is incorporated into the same pharmaceutical formulation as component (b) by e.g. mixing in a conventional way.
The present invention also includes a method of improving the onset of therapeutic action by concomitant administration of a composition comprising of (R)-3-N,N- dicyclobutylamino-8-fluoro-3,4-dihydro-2H- 1 -benzopyran-5-carboxamide hydrogen (2Λ,3_?)-tartrate monohydrate and paroxetine. A further embodiment of the present invention is a kit containing a dosage unit of (R)-3- NN-dicyclobutylamino-8-fluoro-3,4-dihydro-2H- 1 -benzopyran-5-carboxamide hydrogen (2_?,3i?)-tartrate monohydrate and a dosage unit of a paroxetine, optionally with instructions for use.
Pharmaceutical formulations
According to the present invention the compounds in the composition will normally be administered orally, rectally, transdermally, nasally or by injection, in the form of pharmaceutical formulations comprising the active ingredients in a pharmaceutically acceptable dosage form . The dosage form may be a solid, semisolid or liquid formulation. Usually the active substances will constitute between 0.1 and 99% by weight of the formulation, more specifically between 0.5 and 20% by weight for formulations intended for injection and between 0.2 and 50% by weight for formulations suitable for oral administration.
The pharmaceutical formulation comprises the active ingredients, optionally in association with adjuvants, excipients e.g. diluents, and/or inert carriers.
To produce pharmaceutical formulations of the composition of the invention in the form of dosage units for oral application, the selected compounds may be mixed with a solid excipient, e.g. lactose, saccharose, sorbitol, mannitol, starches such as potato starch, corn starch or amylopectin, cellulose derivatives, a binder such as gelatin or poly- vinylpyrrolidone, disintegrants e.g. sodium starch glycolate, cross-linked PVP and cross- caramellose sodium and a lubricant such as magnesium stearate, calcium stearate, polyethylene glycol, waxes, paraffin, and the like, and an antisticking agent such as talc or colloidal silicon dioxide, and then compressed into tablets. If coated tablets are required, the cores, prepared as described above, may be coated with a polymer known to the man skilled in the art e.g. HPMC, HC or other cellulose derivatives or PNP, wherein the polymer is dissolved in water or a readily volatile organic solvent or mixture of organic solvents. Alternatively, the tablets can be coated with a concentrated sugar solution which may contain e.g. gum arabic, gelatin, talcum, titanium dioxide, and the like. Dyestuffs may be added to these coatings for instance in order to readily distinguish between tablets containing different active substances or different amounts of the active compounds.
For the formulation of soft gelatin capsules, the active substances may be admixed with e.g. a vegetable oil or polyethylene glycol. Hard gelatin capsules may contain granules of the active substances using any of the above mentioned excipients for tablets e.g. lactose, saccharose, sorbitol, mannitol, starches (e.g. potato starch, corn starch or amylopectin), cellulose derivatives, plasticizers, polyetheneglycol, waxes, lipids or gelatin. Also liquids or semisolids of the drug can be filled into hard gelatin capsules.
Dosage units for rectal application can be solutions or suspensions or can be prepared in the form of suppositories comprising the active substances in a mixture with a neutral fatty base, or gelatine rectal capsules comprising the active substances in admixture with vegetable oil or paraffin oil. Liquid formulations for oral application may be in the form of solutions, syrups or suspensions, for example "solutions containing from about 0.2% to about 20% by weight of the active substances herein described, the balance being sugar and mixture of ethanol, water, glycerol and propylene glycol. Optionally such liquid formulations" may contain colouring agents, flavouring agents, saccharin and carboxymethyl-cellulose as a thickening agent or other excipients known to a person skilled in the art.
Solutions for parenteral applications by injection can be prepared in an aqueous solution of a water-soluble pharmaceutically acceptable salt of the active substances, preferably in a concentration of from about 0.5% to about 10% by weight. These solutions may also contain stabilizing agents and/or buffering agents and may conveniently be provided in various dosage unit ampoules. Suitable daily doses of the active compounds in the composition of the invention in therapeutic treatment of humans are about 0.01-100 mg/kg bodyweight for peroral administration and 0.001-100 mg kg bodyweight for parenteral administration. The daily doses of the active ingredient C_^-3-NN-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-l- benzopyran-5-carboxamide hydrogen (2i?,3i?)-tartrate monohydrate may very well differ from the daily doses of the active ingredient paroxetine but the doses can also be the same for both of the active ingredients.
Medical and Pharmaceutical Use
In a further aspect the present invention provides the use of the composition comprising a first component (a) which is 'Λ -3-NN-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-l- benzopyran-5-carboxamide hydrogen (2Λ,3i?)-tartrate monohydrate and a second component (b) which is paroxetine, in the treatment of 5-hydroxytryptamine mediated disorders, such as affective disorders. Examples of affective disorders are disorders in the CΝS such as mood disorders (depression, major depressive episodes, dysthymia, seasonal affective disorder, depressive phases of bipolar disorder), anxiety disorders (obsessive compulsive disorder, panic disorder with/without agoraphobia, social phobia, specific phobia, generalized anxiety disorder, posttraumatic stress disorder), personality disorders (disorders of impulse control, trichotellomania) and sleep disorders. Other disorders in the CΝS such as eating disorders (obesity, anorexia, bulimia), premenstrual syndrome, sexual disturbances, alcoholism, tobacco abuse, autism, attention deficit, hyperactivity disorder, migraine, memory disorders (age associated memory impairment, presenile and senile dementia such as Alzheimer's disease), pathological aggression, schizophrenia, endocrine disorders (e g hyperprolactinaemia), stroke, dyskinesia, Parkinson's disease, thermoregulatory disorders, pain and hypertension may also be treated with the combination described herein. Examples of other hydroxytryptamine mediated disorders are urinary incontinence, vasospasm and growth control of tumors (e g lung carcinoma) and it may be possible to treat those with the combination described herein as well. Pharmacology
Antagonism by (ϊf -3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2_ -l-benzopyran- 5-carboxamide hydrogen (2ϋ.3R)-tartrate monohydrate (NAD 299) of the paroxetine induced suppression of dorsal raphe firing.
Materials and methods
Adult male Sprague Dawley rats (B&K Universal, Sollentuna, Sweden) were used and were housed under controlled climate conditions. The animals were prepared for electrophysiological recordings according to standard procedures. Briefly, the rats were deeply anaesthetized with chloral hydrate and mounted in a stereotaxic frame. Extracellular recording electrodes were lowered into the dorsal raphe, guided by stereotaxic co-ordinates, and target neurones were identified by the firing characteristics of serotonin neurones in this nucelus. The animals were kept anaesthetized throughout the experiments and drugs were administered intravenously through a tail vein catheter. Paroxetine (0.1 mg kg i.v.) was administered 3 min before NAD 299 (50 nmol kg i.v.)
Results
It was also found that NAD 299 could antagonize the suppression of firing in serotoninerglc dorsal raphe neurones in rats induced by paroxetine (Figure). The figure shows medians +semi-interquartile range based on recordings from 5 animals per group. Statistical evaluation for differences between treatment groups and controls, performed by means of the Mann-Whitney μ-test, is also shown in the figure. In addition, the paroxetine- induced suppression was statistically significantly antagonised by NAD 299 treatment (p<0.05).
Discussion and conclusions
It is generally considered that selective serotonin reuptake inhibitors (SSRIs), such as paroxetine, owe their antidepressant efficacy to their ability to enhance the synaptic availability of serotonin in forebrain target areas of serotoninergic projections from the midbrain raphe nuclei. However, the 5-hydroxytryptamine (5-HT) transporter protein affected is present both in somatodendritic and terminal regions, and initially the enhanced availability of serotonin in the former areas will inhibit neuronal activity as well as forebrain synthesis and release of 5-HT through activation of inhibitory 5-HTJA autoreceptors. As these receptors desensitize with time there is a gradual increase in forebrain serotonin release, as has been shown in animals studies, and the time-course for this phenomenon probably explains the delayed onset of antidepressant actions clinically.
There exists the hypothesis that disinhibition of the self-inhibitory effects of SSRIs by blockade of inhibitory 5-HTι A autoreceptors should produce a faster onset of action, and also generally increase the efficacy of these agents.
The data show that ^-3-N.N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-l-benzopyran- 5-carboxamide hydrogen (2i?,3Λ)-tartrate monohydrate (NAD 299) effectively antagonizes the inhibition of firing in serotoninergic neurones produced by acute administration of paroxetine in the rat.
The following non-limiting Example serves to illustrate the present invention.
Example
A suitable pharmaceutical composition comprising a first component (a) and a second component (b) in a single dosage form include the following:
Composition mg/tablet
Active drug component (a) 5
Active drug component (b) 20
Microcrystalline cellulose 100
Corn starch 40
Povidone 4
Water 50
Sodium starch glycolate 8
Magnesium stearate 1

Claims

1. A composition comprising of a first component (a) which is (R)-3-N,N- dicyclobutylamino-8-fluoro-3,4-dihydro-2H-l-benzopyran-5-carboxamide hydrogen
(2Λ,3i?)-tartrate monohydrate and a second component (b) which is paroxetine in the form of the free base, or a pharmaceutically acceptable salt and/or solvate thereof.
2. Use of the composition according to claim 1 for the manufacture of a medicament for the treatment of 5-HT mediated disorders.
3. The use according to claim 2 for the manufacture of a medicament for the treatment of affective disorders.
4. The use according to claim 3 for the manufacture of a medicament for the treatment of mood disorders.
5. The use according to claim 4 for the manufacture of a medicament for the treatment of depression.
6. A method for the treatment of 5-HT mediated disorders by administering to a patient suffering therefrom the composition defined in claim 1.
The method according to claim 6 for the treatment of affective disorders.
8. The method according to claim 6 for the treatment of mood disorders.
9. The method according to claim 8 for the treatment of depression.
10. A method of improving the onset of therapeutic action by concomitant administration of a composition defined in claim 1.
11. A pharmaceutical formulation wherein the active ingredients are those in the composition defined in claim 1, optionally in association with adjuvants, excipients and/or inert carriers.
12. A pharmaceutical formulation according to claim 11 wherein the first component (a) is concomitantly administered with the second component (b).
13. A pharmaceutical formulation according to any one of claims 11-12 for use in the treatment of 5-HT mediated disorders.
14. A pharmaceutical formulation according to any one of claims 11-12 for use in the treatment of affective disorders.
15. A pharmaceutical formulation according to any one of claims 11-12 for use in the treatment of mood disorders.
16. A pharmaceutical formulation according to any one of claims 11-12 for use in the treatment of depression.
17. A process for the preparation of the composition according to claim 1 whereby the first component (a) is incorporated into the same pharmaceutical formulation as the second component (b).
18. A process for the preparation of the composition according to claim 1 whereby the first component (a) is in a one pharmaceutical formulation and is combined with the second component (b) is in a different pharmaceutical formulation.
19. A kit containing a dosage unit of a first component (a) which is tϊζ)-3-NN- dicyclobutylamino-8-fluoro-3,4-dihydro-2H-l-benzopyran-5-carboxamide hydrogen (2i.,3i-)-tartrate monohydrate and a dosage unit of a second component (b) which is paroxetine, in the form of the free base, or a pharmaceutically acceptable salt and/or solvate thereof, optionally with instructions for use.
AMENDED CLAIMS
[received by the International Bureau on 15 February 2000 (15.02.00); original claims 6,11 and 19 amended; remaining claims unchanged (3 pages)]
1. A composition comprising of a first component (a) which is (RJ-3-N.N- s dicyclobutylamino-8-fluoro-3 ,4-dihydro-2H- 1 -benzopyran-5-carboxamide hydrogen (2R,3R)-tartrate monohydrate and a second component (b) which is paroxetine in the form of the free base, or a pharmaceutically acceptable salt and/or solvate thereof.
2. Use of the composition according to claim 1 for the manufacture of a medicament for 0 the treatment of 5-HT mediated disorders.
3. The use according to claim 2 for the manufacture of a medicament for the treatment of affective disorders.
4. The use according to claim 3 for the manufacture of a medicament for the treatment of mood disorders.
5. The use according to claim 4 for the manufacture of a medicament for the treatment of depression.
6. The use according to claim 2 in the manufacture of a medicament in the prevention or in the treatment of urinary incontinence.
7. A method for the treatment of 5-HT mediated disorders by administering to a patient suffering therefrom the composition defined in claim 1.
8. The method according to claim 7 for the treatment of affective disorders.
9. The method according to claim 7 for the treatment of mood disorders.
10. The method according to claim 9 for the treatment of depression.
11. A method according to claim 7 for the prevention or the treatment of urinary incontinence.
12. A method of improving the onset of therapeutic action by concomitant administration of a composition defined in claim 1.
13. A pharmaceutical formulation wherein the active ingredients are those in the composition defined in claim 1, optionally in association with adjuvants, excipients and/or inert carriers.
14. A pharmaceutical formulation according to claim 13 wherein the first component (a) is concomitantly administered with the second component (b).
15. A pharmaceutical formulation according to any one of claims 13-14 for use in the treatment of 5-HT mediated disorders.
16. A pharmaceutical formulation according to any one of claims 13-14 for use in the treatment of affective disorders.
17. A pharmaceutical formulation according to any one of claims 13-14 for use in the treatment of mood disorders.
18. A pharmaceutical formulation according to any one of claims 13-14 for use in the treatment of depression.
19. A pharmaceutical formulation according to any one of claims 13-14 for use in the treatment of urinary incontinence.
20. A process for the preparation of the composition according to claim 1 whereby the first component (a) is incorporated into the same pharmaceutical formulation as the second component (b).
21. A process for the preparation of the composition according to claim 1 whereby the first component (a) is in a one pharmaceutical formulation and is combined with the second component (b) is in a different pharmaceutical formulation.
22. A kit containing a dosage unit of a first component (a) which is (R)-3-N,N- dicyclobutylamino-8-fluoro-3,4-dihydro-2H-l-benzopyran-5-carboxamide hydrogen (2R,3R)-tartrate monohydrate and a dosage unit of a second component (b) which is paroxetine, in the form of the free base, or a pharmaceutically acceptable salt and/or solvate thereof, optionally with instructions for use.
PCT/SE1999/001597 1998-09-16 1999-09-13 A new composition WO2000015218A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
PL99346763A PL346763A1 (en) 1998-09-16 1999-09-13 A new composition
BR9913748-8A BR9913748A (en) 1998-09-16 1999-09-13 Composition, use of composition method for the treatment of disorders mediated by 5-ht, method of improving the beginning of therapeutic action, pharmaceutical formulation, process for preparing the composition, and, kit
JP2000569802A JP2002524508A (en) 1998-09-16 1999-09-13 New composition
EP99951319A EP1128825A1 (en) 1998-09-16 1999-09-13 A new composition
SK326-2001A SK3262001A3 (en) 1998-09-16 1999-09-13 A new composition
EEP200100157A EE200100157A (en) 1998-09-16 1999-09-13 New composition
KR1020017003337A KR20010099647A (en) 1998-09-16 1999-09-13 A New Composition
IL14151999A IL141519A0 (en) 1998-09-16 1999-09-13 A new composition of (r) -3-n, n-dicyclobutylamino-8-fluoro-3, 4-dihydro-3h-1-benzopyran-5-carboxamide hydrogen (2r, 3r) - tartrate monohydrate and paroxetine
CA002342341A CA2342341A1 (en) 1998-09-16 1999-09-13 A new composition
AU63780/99A AU6378099A (en) 1998-09-16 1999-09-13 A new composition
IS5879A IS5879A (en) 1998-09-16 2001-03-07 New preparation
NO20011312A NO20011312L (en) 1998-09-16 2001-03-15 New composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9803156A SE9803156D0 (en) 1998-09-16 1998-09-16 A new composition
SE9803156-0 1998-09-16

Publications (1)

Publication Number Publication Date
WO2000015218A1 true WO2000015218A1 (en) 2000-03-23

Family

ID=20412627

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1999/001597 WO2000015218A1 (en) 1998-09-16 1999-09-13 A new composition

Country Status (21)

Country Link
EP (1) EP1128825A1 (en)
JP (1) JP2002524508A (en)
KR (1) KR20010099647A (en)
CN (1) CN1317964A (en)
AR (1) AR021808A1 (en)
AU (1) AU6378099A (en)
BR (1) BR9913748A (en)
CA (1) CA2342341A1 (en)
CZ (1) CZ2001961A3 (en)
EE (1) EE200100157A (en)
HU (1) HUP0103544A3 (en)
ID (1) ID28785A (en)
IL (1) IL141519A0 (en)
IS (1) IS5879A (en)
NO (1) NO20011312L (en)
PL (1) PL346763A1 (en)
SE (1) SE9803156D0 (en)
SK (1) SK3262001A3 (en)
TR (1) TR200100779T2 (en)
WO (1) WO2000015218A1 (en)
ZA (1) ZA200101946B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002030405A2 (en) * 2000-10-13 2002-04-18 Neurosearch A/S Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
EP1859807A1 (en) * 2005-03-04 2007-11-28 Tokyo Medical and Dental University Recurrence preventive therapeutic agent for psychostimulant-induced psychosis and schizophrenia

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996033710A1 (en) * 1995-04-27 1996-10-31 Astra Aktiebolag A combination of a 5-ht uptake inhibitor with a selective 5-ht1a antagonist

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996033710A1 (en) * 1995-04-27 1996-10-31 Astra Aktiebolag A combination of a 5-ht uptake inhibitor with a selective 5-ht1a antagonist

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002030405A2 (en) * 2000-10-13 2002-04-18 Neurosearch A/S Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
WO2002030405A3 (en) * 2000-10-13 2002-09-06 Neurosearch As Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
US7307087B2 (en) 2000-10-13 2007-12-11 Neurosearch A/S Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
EP1859807A1 (en) * 2005-03-04 2007-11-28 Tokyo Medical and Dental University Recurrence preventive therapeutic agent for psychostimulant-induced psychosis and schizophrenia
EP1859807A4 (en) * 2005-03-04 2008-04-23 Univ Tokyo Medical & Dental Recurrence preventive therapeutic agent for psychostimulant-induced psychosis and schizophrenia

Also Published As

Publication number Publication date
EE200100157A (en) 2002-08-15
CA2342341A1 (en) 2000-03-23
HUP0103544A2 (en) 2002-05-29
PL346763A1 (en) 2002-02-25
SK3262001A3 (en) 2001-08-06
JP2002524508A (en) 2002-08-06
EP1128825A1 (en) 2001-09-05
BR9913748A (en) 2001-07-10
CN1317964A (en) 2001-10-17
AU6378099A (en) 2000-04-03
TR200100779T2 (en) 2001-10-22
IL141519A0 (en) 2002-03-10
NO20011312L (en) 2001-05-16
KR20010099647A (en) 2001-11-09
IS5879A (en) 2001-03-07
ID28785A (en) 2001-07-05
HUP0103544A3 (en) 2003-12-29
AR021808A1 (en) 2002-08-07
NO20011312D0 (en) 2001-03-15
SE9803156D0 (en) 1998-09-16
CZ2001961A3 (en) 2001-08-15
ZA200101946B (en) 2002-06-10

Similar Documents

Publication Publication Date Title
US6169098B1 (en) Composition and methods employing it for the treatment of 5-HT-mediated disorders
US8304431B2 (en) Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050203130A1 (en) Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
JP4571485B2 (en) Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US6472423B1 (en) Pharmaceutical composition
EP1128825A1 (en) A new composition
AU6378199A (en) A new composition
AU6378299A (en) A new composition
JP4571645B2 (en) Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1113792A1 (en) A new composition
MXPA01002370A (en) A new composition
MXPA01002543A (en) A new composition
CA2451798C (en) Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99811010.8

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 1999 63780

Country of ref document: AU

Kind code of ref document: A

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 141519

Country of ref document: IL

Ref document number: 63780/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 510188

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2342341

Country of ref document: CA

Ref document number: 2342341

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/00231/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/002370

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2001/01946

Country of ref document: ZA

Ref document number: 200101946

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 3262001

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2000 569802

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017003337

Country of ref document: KR

Ref document number: PV2001-961

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2001/00779

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 1999951319

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2001-961

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1999951319

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017003337

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV2001-961

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1999951319

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020017003337

Country of ref document: KR